Welcome to our dedicated page for Context Therapeutics SEC filings (Ticker: CNTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Context Therapeutics Inc. (CNTX) SEC filings page on Stock Titan provides access to the company’s public regulatory documents, including current reports on Form 8-K and other filings made with the U.S. Securities and Exchange Commission. These filings offer detailed insight into how Context describes its business as a clinical-stage biopharmaceutical company advancing T cell engaging (TCE) bispecific antibodies for solid tumors, along with information on its capital markets activity and Nasdaq listing status.
Recent Forms 8-K furnished by Context include clinical and corporate updates tied to its TCE pipeline. For example, the company has reported Phase 1 dose-escalation progress for CTIM-76, a Claudin 6 x CD3 TCE in patients with ovarian, endometrial, or testicular cancer, and CT-95, a Mesothelin x CD3 TCE in patients with pancreatic, non-small cell lung, ovarian, mesothelioma, and colorectal cancers. Filings also describe CT-202, a Nectin-4 x CD3 TCE in preclinical development, and summarize safety observations, preliminary anti-tumor activity, and planned next steps as of the filing dates.
Other 8-Ks detail capital raising arrangements, such as an at-the-market Sales Agreement and its amendment, including aggregate offering limits, use of proceeds for research and development, working capital, and general corporate purposes, and the agent’s commission structure. Additional filings address Nasdaq minimum bid price notifications, extensions, and the company’s subsequent return to compliance, which are relevant for understanding listing risk and trading status.
On Stock Titan, these filings are paired with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify clinical trial disclosures, financing terms, and listing-related updates. Users can review new CNTX filings as they appear in EDGAR, then rely on AI-generated overviews to navigate complex regulatory language and focus on the sections most relevant to their analysis.
Minai-Azary Jennifer Lynn reported acquisition or exercise transactions in this Form 4 filing.
Context Therapeutics Inc. reported an insider equity award to its Chief Financial Officer, Jennifer Lynn Minai-Azary. She received a stock option covering 275,000 shares of common stock as a grant, not an open-market purchase or sale.
According to the terms, the option vests over four years. 25% of the option vests and becomes exercisable on February 19, 2027, with the remaining balance vesting in equal monthly installments over the following three years, subject to her continued service with the company.
Context Therapeutics Inc. reported that Chief Medical Officer Karen Deborah Chagin acquired a grant of stock options covering 290,000 shares of the company’s stock. The options carry a reported exercise price of $0.0000 per share and are held as direct derivative securities.
According to the vesting terms, 25% of the option award vests and becomes exercisable on February 19, 2027, with the remaining balance vesting in equal monthly installments over the following three years, contingent on her continued service with the company.
Context Therapeutics Inc. reported that Chief Executive Officer Martin A. Lehr received a grant of stock options for 815,000 shares at an exercise price of $0.00 per share. The option vests over four years, with 25% vesting on February 19, 2027 and the rest in equal monthly installments over the following three years, contingent on continued service.
Context Therapeutics Inc. received an updated beneficial ownership report showing that investment firm Great Point Partners, LLC, together with Dr. Jeffrey R. Jay and Ms. Lillian Nordahl, reports beneficial ownership of 4,683,711 shares of common stock, representing 5.10% of the company’s outstanding shares.
The stake is held through Biomedical Value Fund, L.P. and Biomedical Offshore Value Fund, Ltd., for which Great Point acts as investment manager. The reporting persons state the securities were not acquired to change or influence control of Context Therapeutics and jointly file this Schedule 13G/A.
BioImpact LLC filed an amended Schedule 13G reporting beneficial ownership of 10,679,391 shares of Context Therapeutics Inc. common stock. This represents 11.6% of the outstanding common shares. BioImpact has sole voting and sole dispositive power over all reported shares, with no shared power.
The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Context Therapeutics, other than activities solely in connection with a nomination under Rule 240.14a-11.
Soleus Capital-affiliated funds have disclosed a 5.2% passive stake in Context Therapeutics Inc. common stock. The group reports beneficial ownership of 4,776,398 shares of Context’s common stock, based on 91,879,177 shares outstanding as of November 4, 2025.
The shares are held directly by Soleus Capital Master Fund, L.P., with related Soleus entities and Guy Levy reporting shared voting and dispositive power and formally disclaiming beneficial ownership beyond Section 13(d) reporting obligations. They certify the holdings were not acquired to change or influence control of Context Therapeutics.
Context Therapeutics Inc. furnished an updated corporate presentation dated January 2026 for use in meetings with investors, analysts and other stakeholders. The presentation is provided as Exhibit 99.1 to this report and is incorporated by reference for informational purposes. The company states that the materials in Item 7.01 and Exhibit 99.1 are being furnished, not filed, meaning they are not subject to certain liability provisions of the Exchange Act and are not automatically incorporated into other Securities Act or Exchange Act filings.
Context Therapeutics (CNTX) announced pipeline updates alongside its third-quarter 2025 communication. The company highlighted progress in three bispecific T cell engager programs across early development.
CTIM-76 (CLDN6 x CD3) Phase 1: 12 patients enrolled as of October 30, 2025; currently in Cohort 5 with a 140 mcg priming dose and 560 mcg full dose. Preliminary signs of anti-tumor activity, including an ongoing RECIST response, were observed beginning at Cohort 3. No CRS greater than Grade 1, no dose-limiting toxicities, and the maximum tolerated dose has not been reached. The company plans updated interim Phase 1a data and Phase 1b dose selection in the second quarter of 2026.
CT-95 (MSLN x CD3) Phase 1: 6 patients enrolled; in Cohort 3 with a 0.18 µg/kg priming dose and 0.6 µg/kg full dose. Based on preclinical work, target dose exposure is projected starting at Cohort 4. No CRS greater than Grade 2, no DLTs, and no MTD reached. Initial Phase 1a data are anticipated mid‑2026.
CT-202 (Nectin‑4 x CD3): preclinical program expects regulatory filings to support a first‑in‑human trial in the second quarter of 2026.
Context Therapeutics (CNTX) reported Q3 2025 results showing continued investment in its T‑cell engager pipeline and a narrower quarterly loss. Net loss was $9,693,237 versus $17,459,893 a year ago, as research and development declined year over year. Cash and cash equivalents were $76,938,183 as of September 30, 2025, supporting operations the company indicates extend into 2027.
R&D expense was $8,722,104, driven by CT‑202 manufacturing and preclinical work and ongoing trials for CTIM‑76 and CT‑95; general and administrative was $1,888,376. The company dosed first patients in CTIM‑76 (January 2025) and CT‑95 (April 2025) Phase 1 studies and plans to share initial readouts in 2026. In October 2025, CNTX achieved a $2,000,000 development milestone under the BioAtla agreement, and on November 3, 2025, it entered a CT‑202 license with Lonza covering manufacturing IP.
Capital resources include an amended at‑the‑market facility filed on October 24, 2025 permitting sales of up to $75,000,000 of common stock (exclusive of shares sold in 2024). Shares outstanding were 91,879,177 as of November 4, 2025.
Context Therapeutics Inc. amended its at-the-market equity program with Leerink Partners, allowing the company to offer and sell common stock with an aggregate offering price of up to $75.0 million as of October 24, 2025, exclusive of shares previously sold under its prior ATM prospectus.
Under the prior ATM prospectus dated December 2, 2024, the company sold 14,705,882 shares for an aggregate offering price of approximately $15.0 million. The amended program will use the company’s Form S-3 (File No. 333-283037), declared effective on November 14, 2024, as supplemented on October 24, 2025.
Leerink Partners will receive a commission of up to 3.0% of gross proceeds. Context plans to use any net proceeds for research and development, working capital, and general corporate purposes, which may include asset acquisitions. The company also suspended and terminated the prior ATM sales prospectus.